Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 5/20 | 0.38 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215217 | 1.00 | GPR119 (0.42) | GPR119RAB9AHPGDSTTKFASN | |
| SCHEMBL2394389 | 0.90 | GPR119 (0.42) | GPR119RAB9AHPGDSTTKFASN | |
| SCHEMBL2398405 | 0.90 | GPR119 (0.42) | GPR119RAB9AHPGDSTTKFASN | |
| SCHEMBL2395228 | 0.90 | GPR119 (0.42) | GPR119RAB9AHPGDSTTKOPRK1 | |
| SCHEMBL2395225 | 0.90 | GPR119 (0.42) | GPR119RAB9AHPGDSTTKOPRK1 | |
| SCHEMBL2394392 | 0.90 | GPR119 (0.42) | GPR119RAB9AHPGDSTTKFASN | |
| SCHEMBL2392621 | 0.89 | GPR119 (0.47) | GPR119RAB9AHPGDSABL1BMPR1B | |
| SCHEMBL2392624 | 0.89 | GPR119 (0.47) | GPR119RAB9AHPGDSABL1BMPR1B | |
| SCHEMBL1844454 | 0.86 | GPR119 (0.39) | GPR119RAB9A | |
| SCHEMBL1842605 | 0.85 | GPR119 (0.38) | GPR119RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885RAB9A 585/4885HPGDS 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.